Article info

Download PDFPDF

Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe

Authors

  1. Correspondence to Dr Daniele Barbaro; danielebarbaro1970{at}libero.it
View Full Text

Citation

Barbaro D, Lapi P, Viacava P, et al
Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe

Publication history

  • Accepted November 12, 2020
  • First published December 22, 2020.
Online issue publication 
December 22, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.